Type II cGMP-dependent protein kinase inhibits ligand‑induced activation of EGFR in gastric cancer cells

Jiang,Lu; Chen,Yongchang; Li,Yueying; Lan,Ting; Wu,Min; Wang,Ying; Qian,Hai

doi:10.3892/mmr.2014.1942

Type II cGMP-dependent protein kinase inhibits ligand‑induced activation of EGFR in gastric cancer cells

Authors:
- Lu Jiang
- Yongchang Chen
- Yueying Li
- Ting Lan
- Min Wu
- Ying Wang
- Hai Qian
View Affiliations

Affiliations: Department of Physiology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
Published online on: February 10, 2014 https://doi.org/10.3892/mmr.2014.1942
Pages: 1405-1409

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous data demonstrated that type II cGMP‑dependent protein kinase (PKG II) inhibited epidermal growth factor (EGF)-induced MAPK/ERK/JNK‑mediated signal transduction through inhibiting the phosphorylation/activation of the epidermal growth factor receptor (EGFR). Since the EGFR also binds with several other ligands as well as EGF, the present study was designed to investigate whether PKG II inhibited transforming growth factor-α (TGF-α), betacellulin (BTC) and epiregulin (EPR) induced phosphorylation/activation of the EGFR and consequent MAPK/ERK‑mediated signaling. The human gastric cancer cell line AGS, was infected with adenoviral constructs encoding cDNA of PKG II (Ad-PKG II) to increase the expression of PKG II and was treated with 8-pCPT‑cGMP to activate the kinase. Western blotting was applied to detect the phosphorylation of EGFR and MAPK/ERK. The results demonstrated that treatment with EGF (100 ng/ml, 5 min), TGF-α (100 ng/ml, 5 min), BTC (100 ng/ml, 5 min) and EPR (100 ng/ml, 5 min) increased the tyrosine (tyr) 1068 phosphorylation of the EGFR and the threonine (thr) 202/tyr 204 phosphorylation of MAPK/ERK. Infecting the cells with Ad-PKG II and stimulating the kinase with 8-pCPT-cGMP efficiently inhibited the phosphorylation of the EGFR and MAPK/ERK induced by EGF, TGF-α, BTC and EPR. The results indicated that PKG II also inhibits the activation of the EGFR caused by diverse ligands of the receptor.

View Figures

View References

1	Shah MA and Schwartz GK: Treatment of metastatic esophagus and gastric cancer. Semin Oncol. 31:574–587. 2004. View Article : Google Scholar : PubMed/NCBI
2	Becker JC, Muller-Tidow C, Serve H, et al: Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol. 12:3297–3305. 2006.PubMed/NCBI
3	Arnold D, Peinert S, Voigt W, et al: Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist. 11:602–611. 2006. View Article : Google Scholar : PubMed/NCBI
4	Johnston JB, Navaratnam S, Pitz MW, et al: Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 13:3483–3492. 2006. View Article : Google Scholar : PubMed/NCBI
5	Astsaturov I, Cohen RB and Harari PM: EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 6:691–710. 2006. View Article : Google Scholar : PubMed/NCBI
6	Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1:2005.0010. 2005.PubMed/NCBI
7	Yarden Y and Shilo BZ: SnapShot: EGFR signaling pathway. Cell. 131:10182007. View Article : Google Scholar : PubMed/NCBI
8	Arteaga CL: Overview of epidermal growth factor receptor biology and its role as therapeutic taget in human neoplasia. Semin Oncol. 29:3–9. 2002. View Article : Google Scholar : PubMed/NCBI
9	Krozely P: Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs. 8:163–168. 2004. View Article : Google Scholar : PubMed/NCBI
10	Cook AL and Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal. 16:253–261. 2004. View Article : Google Scholar : PubMed/NCBI
11	Swartling FJ, Ferletta M, Kastemar M, et al: Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131. 2009. View Article : Google Scholar : PubMed/NCBI
12	Fallahian F, Karami-Tehrani F, Salami S, et al: Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 278:3360–3369. 2011. View Article : Google Scholar : PubMed/NCBI
13	Swartling FJ, Ferletta M, Kastemar M, et al: Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wang R, Kwon IK, Thangaraju M, et al: Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa. Am J Physiol Gastrointest Liver Physiol. 303:G209–G219. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chen YC, Ren F, Sang JR, et al: Type II cGMP-dependent protein kinase inhibits proliferation of the gastric cancer cell line BGC-823. Mol Med Rep. 3:361–366. 2010.PubMed/NCBI
16	Jiang L, Lan T, Chen Y, et al: PKG II inhibits EGF/EGFR-induced migration of gastric cancer cells. PLoS One. 8:e616742013. View Article : Google Scholar : PubMed/NCBI
17	Wu Y, Chen Y, Qu R, et al: Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells. Oncol Rep. 27:553–558. 2012.PubMed/NCBI
18	Lan T, Chen Y, Sang J, et al: Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol Rep. 27:2039–2044. 2012.PubMed/NCBI
19	Harris RC, Chung E and Coffey RJ: EGF receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar
20	Prigent SA and Lemoine NR: The type I (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 4:1–24. 1992. View Article : Google Scholar : PubMed/NCBI
21	Barnard JA, Beauchamp RD, Russell WE, et al: Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology. 108:564–580. 1995. View Article : Google Scholar : PubMed/NCBI
22	D’Agnano I, D’Angelo C, Savarese A, et al: DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. Lab Invest. 72:432–438. 1995.PubMed/NCBI
23	Wells A: EGF receptor. Int J Biochem Cell Biol. 31:637–643. 1999. View Article : Google Scholar
24	Takemura S, Yashiro M, Sunami T, et al: Novel models for human scirrhous gastric carcinoma in vivo. Cancer Sci. 95:893–900. 2004. View Article : Google Scholar : PubMed/NCBI
25	Wang C, Lv X, Jiang C, et al: Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways. PLoS One. 7:e482992012.
26	Dias A, Garcia C, Majewski M, et al: Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study. Dig Dis Sci. 56:3220–3225. 2011. View Article : Google Scholar
27	Yoshida K, Kyo E, Tsujino T, et al: Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth. Jpn J Cancer Res. 81:43–51. 1990. View Article : Google Scholar
28	Sasada R, Ono Y, Taniyama Y, et al: Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family. Biochem Biophys Res Commun. 190:1173–1179. 1993. View Article : Google Scholar : PubMed/NCBI
29	Dunbar AJ and Goddard C: Structure-function and biological role of betacellulin. Int J Biochem Cell Biol. 32:805–815. 2000. View Article : Google Scholar : PubMed/NCBI
30	Shing Y, Christofori G, Hanahan D, et al: Betacellulin: a mitogen from pancreatic beta cell tumors. Science. 259:1604–1607. 1993. View Article : Google Scholar : PubMed/NCBI
31	Seno M, Tada H, Kosaka M, et al: Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. Growth Factors. 13:181–191. 1996. View Article : Google Scholar : PubMed/NCBI
32	Toyoda H, Komurasaki T, Uchida D, et al: Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem. 270:7495–7500. 1995.PubMed/NCBI
33	Toyoda H, Komurasaki T, Uchida D, et al: Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J. 326:69–75. 1997.PubMed/NCBI
34	Das SK, Das N, Wang J, et al: Expression of betacellulin and epiregulin genes in the mouse uterus temporally by the blastocyst solely at the site of its apposition is coincident with the “window” of implantation. Dev Biol. 190:178–190. 1997.PubMed/NCBI
35	Komurasaki T, Toyoda H, Uchida D, et al: Mechanism of growth promoting activity of epiregulin in primary cultures of rat hepatocytes. Growth Factors. 20:61–69. 2002. View Article : Google Scholar : PubMed/NCBI
36	Shirakata Y, Komurasaki T, Toyoda H, et al: Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem. 275:5748–5753. 2000. View Article : Google Scholar : PubMed/NCBI
37	Rangaswami H, Marathe N, Zhuang S, et al: Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J Biol Chem. 284:14796–14808. 2009. View Article : Google Scholar : PubMed/NCBI
38	Nie HG, Chen L, Han DY, et al: Regulation of epithelial sodium channels by cGMP/PKGII. J Physiol. 587:2663–2676. 2009. View Article : Google Scholar : PubMed/NCBI